412 reports of this reaction
1.2% of all OLAPARIB reports
#15 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #15 most commonly reported adverse reaction for OLAPARIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 412 FDA adverse event reports linking OLAPARIB to HAEMOGLOBIN DECREASED. This represents approximately 1.2% of all 33,417 adverse event reports for this drug.
Patients taking OLAPARIB who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for OLAPARIB, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for OLAPARIB:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 412 FDA reports for OLAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 1.2% of all adverse event reports for OLAPARIB, making it a notable side effect.
If you experience haemoglobin decreased while taking OLAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.